Olanzapine and samidorphan
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
Alixorexton
Narcolepsy Type 1
Phase 2
Narcolepsy Type 2
Phase 2
Idiopathic Hypersomnia
Phase 2
Alixorexton (formerly ALKS 2680) is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
Alixorexton is currently being evaluated in a global phase 2 program. Vibrance-1, a phase 2 study in adults with narcolepsy type 1, has completed enrollment. Vibrance-2, a phase 2 study in adults with narcolepsy type 2, and Vibrance-3, a phase 2 study in adults with idiopathic hypersomnia are ongoing. Participants who complete one of the Vibrance studies have the option to continue in a long-term, open-label, safety study evaluating the safety of alixorexton for up to two years.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:
ALKS 4510
Neuroscience Indications
Phase 1
ALKS 4510 is an investigational orexin 2 receptor agonist in developement for the treatment of central nervous system disorders. It is currently being evaluted in a phase 1 study in healthy volunteers.
ALKS 7290
Neuroscience Indications
Preclinical
ALKS 7290 is an investigational orexin 2 receptor agonist being evaluated preclinically for the treatment of central nervous system disorders.